Press release
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":" NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company's Chief Executive Officer, Nadav Kidron, will present and participate in one-on-one meetings at the 2019 Ladenburg Thalmann Healthcare Conference to be held on September 24, 2019 in New York, NY.\n Details of the presentation: Ladenburg Thalmann 2019 Healthcare ConferenceDate: September 24, 2019Time: 3:00 – 3:25 p.m. ETSection: Track 5 – MontmartreLocation: Sofitel, New York, New YorkPresenter: Nadav Kidron, Chief Executive Officer\nAbout Oramed \nOramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (PODTM) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of Type 2 and Type 1 diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901, which has potential to be the first orally-ingestible GLP-1 analog. For more information, please visit www.oramed.com\nForward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent prot...